OCT Angiography for Retinopathy
(OCTA-RVD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is OCT Angiography safe for humans?
How does OCT Angiography differ from other treatments for retinopathy?
OCT Angiography is unique because it provides high-resolution, three-dimensional images of the eye's blood vessels without needing contrast dyes, allowing for detailed monitoring and diagnosis of retinal diseases. This non-invasive imaging technique offers a wider field of view and higher resolution compared to traditional methods like fluorescein angiography, making it a valuable tool for early detection and disease monitoring.678910
What data supports the effectiveness of the treatment Axial Length Measurement Device, OCTA, Optical Coherence Tomography Angiography, Fundus Imaging, Spectral-Domain OCT Angiography, and Swept-Source OCT Angiography for retinopathy?
Research shows that Optical Coherence Tomography Angiography (OCTA) can effectively image the blood vessels in the eye, which is important for diagnosing and monitoring conditions like diabetic retinopathy. The use of advanced OCTA technologies, such as swept-source OCTA, provides high-resolution images that can help detect changes in the eye's blood vessels, potentially improving the management of retinopathy.36111213
Who Is on the Research Team?
Amir Kashani, MD, MPH
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for individuals with retinal vascular diseases like diabetic retinopathy or retinal vein occlusion, as well as those with high blood pressure that may affect the retina. Participants should be able to undergo regular imaging tests to track changes in their eye condition over time.Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Assessment
Subjects undergo non-invasive, minimal risk, FDA approved diagnostic imaging procedures to identify vascular changes
Follow-up
Participants are monitored for safety and effectiveness after imaging and assessments
What Are the Treatments Tested in This Trial?
Interventions
- Axial Length Measurement Device
- Fundus Imaging
- Spectral-Domain OCT Angiography
- Swept-Source OCT Angiography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Eye Institute (NEI)
Collaborator